Ospedale San Martino

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease2 trials
• Metastatic breast cancer2 trials
• Childhood cancers1 trial
• Chronic kidney disease1 trial
• Cytomegalovirus infection1 trial
• Heart failure1 trial
• Lung cancer1 trial
• Obesity1 trial
• Ovarian cancer1 trial
• Peripheral artery disease1 trial
• Stroke1 trial
• Type 2 diabetes1 trial
• and 1 more

Phase

• Phase 34 trials
• Phase 41 trial

Status

• Active, not recruiting2 trials
• Completed2 trials
• Not yet recruiting2 trials
• Recruiting2 trials
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company4 trials
• Consorzio Futuro in Ricerca1 trial
• Erasme University Hospital1 trial
• European Society for Blood and Marrow Transplantation1 trial
• Fondazione IRCCS Istituto Nazionale dei Tumori, Milano1 trial
• and 1 more

Running trials

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

  Contact: Lucia Del Mastro (principal investigator)

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

  Contact: Carlo Genova (principal investigator)

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

  NCT05234723· IRCCS Azienda Ospedaliero-Universitaria di Bologna· Source

  Contact: Malgorzata Mikulska

• Recruiting

  Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

  NCT06805812· Fondazione IRCCS Istituto Nazionale dei Tumori, Milano· Source

  Contact: Matteo Lambertini

• Active, not recruiting

  A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

  NCT03519945· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer2 recruiting
• Cytomegalovirus infection1 recruiting
• Lung cancer1 recruiting

Closed trials

• Completed

  Barriers Limiting OCT Penetration in Clinical Practice

  NCT07193693· Consorzio Futuro in Ricerca· Source

• Completed

  Central Nervous System Disorders Following Hematopoietic Stem Cell Transplantation

  NCT04737785· European Society for Blood and Marrow Transplantation· Source

• Terminated

  Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)

  NCT04289805· Phase 4· Erasme University Hospital· Source